Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma

Makoto Nakagawa, Fumihiko Nakatani, Hironori Matsunaga, Takahiko Seki, Makoto Endo, Yoko Ogawara, Yukino Machida, Takuo Katsumoto, Kazutsune Yamagata, Ayuna Hattori, Shuhei Fujita, Yukiko Aikawa, Takamasa Ishikawa, Tomoyoshi Soga, Akira Kawai, Hirokazu Chuman, Nobuhiko Yokoyama, Suguru Fukushima, Kenichiro Yahiro, Atsushi KimuraEijiro Shimada, Takeshi Hirose, Toshifumi Fujiwara, Nokitaka Setsu, Yoshihiro Matsumoto, Yukihide Iwamoto, Yasuharu Nakashima, Issay Kitabayashi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Chondrosarcoma is the second most common malignant bone tumor. It is characterized by low vascularity and an abundant extracellular matrix, which confer these tumors resistance to chemotherapy and radiotherapy. There are currently no effective treatment options for relapsed or dedifferentiated chondrosarcoma, and new targeted therapies need to be identified. Isocitrate dehydrogenase (IDH) mutations, which are detected in ~50% of chondrosarcoma patients, contribute to malignant transformation by catalyzing the production of 2-hydroxyglutarate (2-HG), a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Mutant IDH inhibitors are therefore potential novel anticancer drugs in IDH mutant tumors. Here, we examined the efficacy of the inhibition of mutant IDH1 as an antitumor approach in chondrosarcoma cells in vitro and in vivo, and investigated the association between the IDH mutation and chondrosarcoma cells. DS-1001b, a novel, orally bioavailable, selective mutant IDH1 inhibitor, impaired the proliferation of chondrosarcoma cells with IDH1 mutations in vitro and in vivo, and decreased 2-HG levels. RNA-seq analysis showed that inhibition of mutant IDH1 promoted chondrocyte differentiation in the conventional chondrosarcoma L835 cell line and caused cell cycle arrest in the dedifferentiated JJ012 cell line. Mutant IDH1-mediated modulation of SOX9 and CDKN1C expression regulated chondrosarcoma tumor progression, and DS-1001b upregulated the expression of these genes via a common mechanism involving the demethylation of H3K9me3. DS-1001b treatment reversed the epigenetic changes caused by aberrant histone modifications. The present data strongly suggest that inhibition of mutant IDH1 is a promising therapeutic approach in chondrosarcoma, particularly for the treatment of relapsed or dedifferentiated chondrosarcoma.

Original languageEnglish
Pages (from-to)6835-6849
Number of pages15
JournalOncogene
Volume38
Issue number42
DOIs
Publication statusPublished - Oct 17 2019

Fingerprint

Histone Code
Chondrosarcoma
Isocitrate Dehydrogenase
Neoplasms
Mutation
Therapeutics
Dioxygenases
Cell Line
Chondrocytes
Cell Cycle Checkpoints
Epigenomics
Extracellular Matrix
Radiotherapy

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma. / Nakagawa, Makoto; Nakatani, Fumihiko; Matsunaga, Hironori; Seki, Takahiko; Endo, Makoto; Ogawara, Yoko; Machida, Yukino; Katsumoto, Takuo; Yamagata, Kazutsune; Hattori, Ayuna; Fujita, Shuhei; Aikawa, Yukiko; Ishikawa, Takamasa; Soga, Tomoyoshi; Kawai, Akira; Chuman, Hirokazu; Yokoyama, Nobuhiko; Fukushima, Suguru; Yahiro, Kenichiro; Kimura, Atsushi; Shimada, Eijiro; Hirose, Takeshi; Fujiwara, Toshifumi; Setsu, Nokitaka; Matsumoto, Yoshihiro; Iwamoto, Yukihide; Nakashima, Yasuharu; Kitabayashi, Issay.

In: Oncogene, Vol. 38, No. 42, 17.10.2019, p. 6835-6849.

Research output: Contribution to journalArticle

Nakagawa, M, Nakatani, F, Matsunaga, H, Seki, T, Endo, M, Ogawara, Y, Machida, Y, Katsumoto, T, Yamagata, K, Hattori, A, Fujita, S, Aikawa, Y, Ishikawa, T, Soga, T, Kawai, A, Chuman, H, Yokoyama, N, Fukushima, S, Yahiro, K, Kimura, A, Shimada, E, Hirose, T, Fujiwara, T, Setsu, N, Matsumoto, Y, Iwamoto, Y, Nakashima, Y & Kitabayashi, I 2019, 'Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma', Oncogene, vol. 38, no. 42, pp. 6835-6849. https://doi.org/10.1038/s41388-019-0929-9
Nakagawa, Makoto ; Nakatani, Fumihiko ; Matsunaga, Hironori ; Seki, Takahiko ; Endo, Makoto ; Ogawara, Yoko ; Machida, Yukino ; Katsumoto, Takuo ; Yamagata, Kazutsune ; Hattori, Ayuna ; Fujita, Shuhei ; Aikawa, Yukiko ; Ishikawa, Takamasa ; Soga, Tomoyoshi ; Kawai, Akira ; Chuman, Hirokazu ; Yokoyama, Nobuhiko ; Fukushima, Suguru ; Yahiro, Kenichiro ; Kimura, Atsushi ; Shimada, Eijiro ; Hirose, Takeshi ; Fujiwara, Toshifumi ; Setsu, Nokitaka ; Matsumoto, Yoshihiro ; Iwamoto, Yukihide ; Nakashima, Yasuharu ; Kitabayashi, Issay. / Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma. In: Oncogene. 2019 ; Vol. 38, No. 42. pp. 6835-6849.
@article{c796b18381ce477485f9e6a40eefe527,
title = "Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma",
abstract = "Chondrosarcoma is the second most common malignant bone tumor. It is characterized by low vascularity and an abundant extracellular matrix, which confer these tumors resistance to chemotherapy and radiotherapy. There are currently no effective treatment options for relapsed or dedifferentiated chondrosarcoma, and new targeted therapies need to be identified. Isocitrate dehydrogenase (IDH) mutations, which are detected in ~50{\%} of chondrosarcoma patients, contribute to malignant transformation by catalyzing the production of 2-hydroxyglutarate (2-HG), a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Mutant IDH inhibitors are therefore potential novel anticancer drugs in IDH mutant tumors. Here, we examined the efficacy of the inhibition of mutant IDH1 as an antitumor approach in chondrosarcoma cells in vitro and in vivo, and investigated the association between the IDH mutation and chondrosarcoma cells. DS-1001b, a novel, orally bioavailable, selective mutant IDH1 inhibitor, impaired the proliferation of chondrosarcoma cells with IDH1 mutations in vitro and in vivo, and decreased 2-HG levels. RNA-seq analysis showed that inhibition of mutant IDH1 promoted chondrocyte differentiation in the conventional chondrosarcoma L835 cell line and caused cell cycle arrest in the dedifferentiated JJ012 cell line. Mutant IDH1-mediated modulation of SOX9 and CDKN1C expression regulated chondrosarcoma tumor progression, and DS-1001b upregulated the expression of these genes via a common mechanism involving the demethylation of H3K9me3. DS-1001b treatment reversed the epigenetic changes caused by aberrant histone modifications. The present data strongly suggest that inhibition of mutant IDH1 is a promising therapeutic approach in chondrosarcoma, particularly for the treatment of relapsed or dedifferentiated chondrosarcoma.",
author = "Makoto Nakagawa and Fumihiko Nakatani and Hironori Matsunaga and Takahiko Seki and Makoto Endo and Yoko Ogawara and Yukino Machida and Takuo Katsumoto and Kazutsune Yamagata and Ayuna Hattori and Shuhei Fujita and Yukiko Aikawa and Takamasa Ishikawa and Tomoyoshi Soga and Akira Kawai and Hirokazu Chuman and Nobuhiko Yokoyama and Suguru Fukushima and Kenichiro Yahiro and Atsushi Kimura and Eijiro Shimada and Takeshi Hirose and Toshifumi Fujiwara and Nokitaka Setsu and Yoshihiro Matsumoto and Yukihide Iwamoto and Yasuharu Nakashima and Issay Kitabayashi",
year = "2019",
month = "10",
day = "17",
doi = "10.1038/s41388-019-0929-9",
language = "English",
volume = "38",
pages = "6835--6849",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "42",

}

TY - JOUR

T1 - Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma

AU - Nakagawa, Makoto

AU - Nakatani, Fumihiko

AU - Matsunaga, Hironori

AU - Seki, Takahiko

AU - Endo, Makoto

AU - Ogawara, Yoko

AU - Machida, Yukino

AU - Katsumoto, Takuo

AU - Yamagata, Kazutsune

AU - Hattori, Ayuna

AU - Fujita, Shuhei

AU - Aikawa, Yukiko

AU - Ishikawa, Takamasa

AU - Soga, Tomoyoshi

AU - Kawai, Akira

AU - Chuman, Hirokazu

AU - Yokoyama, Nobuhiko

AU - Fukushima, Suguru

AU - Yahiro, Kenichiro

AU - Kimura, Atsushi

AU - Shimada, Eijiro

AU - Hirose, Takeshi

AU - Fujiwara, Toshifumi

AU - Setsu, Nokitaka

AU - Matsumoto, Yoshihiro

AU - Iwamoto, Yukihide

AU - Nakashima, Yasuharu

AU - Kitabayashi, Issay

PY - 2019/10/17

Y1 - 2019/10/17

N2 - Chondrosarcoma is the second most common malignant bone tumor. It is characterized by low vascularity and an abundant extracellular matrix, which confer these tumors resistance to chemotherapy and radiotherapy. There are currently no effective treatment options for relapsed or dedifferentiated chondrosarcoma, and new targeted therapies need to be identified. Isocitrate dehydrogenase (IDH) mutations, which are detected in ~50% of chondrosarcoma patients, contribute to malignant transformation by catalyzing the production of 2-hydroxyglutarate (2-HG), a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Mutant IDH inhibitors are therefore potential novel anticancer drugs in IDH mutant tumors. Here, we examined the efficacy of the inhibition of mutant IDH1 as an antitumor approach in chondrosarcoma cells in vitro and in vivo, and investigated the association between the IDH mutation and chondrosarcoma cells. DS-1001b, a novel, orally bioavailable, selective mutant IDH1 inhibitor, impaired the proliferation of chondrosarcoma cells with IDH1 mutations in vitro and in vivo, and decreased 2-HG levels. RNA-seq analysis showed that inhibition of mutant IDH1 promoted chondrocyte differentiation in the conventional chondrosarcoma L835 cell line and caused cell cycle arrest in the dedifferentiated JJ012 cell line. Mutant IDH1-mediated modulation of SOX9 and CDKN1C expression regulated chondrosarcoma tumor progression, and DS-1001b upregulated the expression of these genes via a common mechanism involving the demethylation of H3K9me3. DS-1001b treatment reversed the epigenetic changes caused by aberrant histone modifications. The present data strongly suggest that inhibition of mutant IDH1 is a promising therapeutic approach in chondrosarcoma, particularly for the treatment of relapsed or dedifferentiated chondrosarcoma.

AB - Chondrosarcoma is the second most common malignant bone tumor. It is characterized by low vascularity and an abundant extracellular matrix, which confer these tumors resistance to chemotherapy and radiotherapy. There are currently no effective treatment options for relapsed or dedifferentiated chondrosarcoma, and new targeted therapies need to be identified. Isocitrate dehydrogenase (IDH) mutations, which are detected in ~50% of chondrosarcoma patients, contribute to malignant transformation by catalyzing the production of 2-hydroxyglutarate (2-HG), a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Mutant IDH inhibitors are therefore potential novel anticancer drugs in IDH mutant tumors. Here, we examined the efficacy of the inhibition of mutant IDH1 as an antitumor approach in chondrosarcoma cells in vitro and in vivo, and investigated the association between the IDH mutation and chondrosarcoma cells. DS-1001b, a novel, orally bioavailable, selective mutant IDH1 inhibitor, impaired the proliferation of chondrosarcoma cells with IDH1 mutations in vitro and in vivo, and decreased 2-HG levels. RNA-seq analysis showed that inhibition of mutant IDH1 promoted chondrocyte differentiation in the conventional chondrosarcoma L835 cell line and caused cell cycle arrest in the dedifferentiated JJ012 cell line. Mutant IDH1-mediated modulation of SOX9 and CDKN1C expression regulated chondrosarcoma tumor progression, and DS-1001b upregulated the expression of these genes via a common mechanism involving the demethylation of H3K9me3. DS-1001b treatment reversed the epigenetic changes caused by aberrant histone modifications. The present data strongly suggest that inhibition of mutant IDH1 is a promising therapeutic approach in chondrosarcoma, particularly for the treatment of relapsed or dedifferentiated chondrosarcoma.

UR - http://www.scopus.com/inward/record.url?scp=85070791724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070791724&partnerID=8YFLogxK

U2 - 10.1038/s41388-019-0929-9

DO - 10.1038/s41388-019-0929-9

M3 - Article

C2 - 31406254

AN - SCOPUS:85070791724

VL - 38

SP - 6835

EP - 6849

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 42

ER -